SanegeneBio Secures $1.7 Billion RNAi Licensing Deal with Genentech
核心洞察
SanegeneBio (搜索) has entered into a global licensing agreement with Genentech, granting exclusive worldwide rights to one of its RNAi programs for $200 million upfront.
The deal includes potential milestone payments totaling up to $1.5 billion plus tiered royalties, representing one of the largest RNAi licensing agreements.
Genentech will lead all future clinical development and commercialization activities while SanegeneBio (搜索) handles early development work.
SanegeneBio (搜索), a clinical-stage biotechnology company developing innovative RNAi therapeutics, has announced a major global licensing agreement with Genentech, a member of the Roche Group, valued at up to $1.7 billion. The deal grants Genentech exclusive worldwide rights to develop and commercialize one of SanegeneBio's RNAi programs based on its proprietary platform technology.
Financial Terms and Structure
Under the agreement terms, SanegeneBio (搜索) will receive an upfront payment of $200 million and remains eligible for development and commercialization milestone payments totaling up to $1.5 billion, plus tiered royalties on potential future product sales. The partnership structure divides responsibilities, with SanegeneBio handling early development activities while Genentech leads all subsequent clinical development and commercialization efforts globally.
Technology Platform and Innovation
SanegeneBio (搜索)'s proprietary RNAi platform incorporates novel chemistries and delivery technologies designed to generate potential breakthrough siRNA medicines across multiple disease areas. The company's technology includes its industry-leading LEAD™ tissue-selective RNAi delivery technology, which enables targeted therapeutic delivery.
"Entering into this agreement with Genentech marks another important milestone for our innovative and differentiated RNAi chemistry and delivery platforms," said Weimin Wang, Ph.D., Chief Executive Officer and Founder of SanegeneBio (搜索). "We are delighted to work with a global scientific leader to continue delivering effective and life-changing therapies for patients worldwide."
Company Background and Pipeline
Founded in 2021 and led by a team of RNAi veterans, SanegeneBio (搜索) operates R&D facilities in Boston, Shanghai, and Suzhou. The company has built a fast-growing pipeline that includes experimental medicines targeting autoimmune nephropathies (搜索), obesity (搜索), and cardiometabolic indications (搜索). To date, SanegeneBio has initiated clinical trials for four experimental medicines, focusing on developing potential best-in-class and first-in-class therapeutics.
The collaboration with Genentech represents a significant validation of SanegeneBio (搜索)'s RNAi technology platform and positions the company to advance its vision that RNAi technology will power blockbuster medicines across diverse therapeutic areas, ultimately improving quality of life and longevity for patients worldwide.